Avoid common mistakes on your manuscript.
1 Erratum to: Drugs (2013) 73:979–988 DOI 10.1007/s40265-013-0064-9
Page 979, column 2, section 1, paragraph 1, lines 9–11: which previously read:
“pioglitazone), and dipeptidyl peptidase-4 inhibitors (e.g. sitagliptin, saxagliptin, linagliptin), and the injectable meglitinides (e.g. repaglinide, nateglinide), glucagon-like”
should read:
“pioglitazone), dipeptidyl peptidase-4 inhibitors (e.g. sitagliptin, saxagliptin, linagliptin) and meglitinides (e.g. repaglinide, nateglinide), and the injectable glucagon-like”
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40265-013-0064-9.
Rights and permissions
About this article
Cite this article
Elkinson, S., Scott, L.J. Erratum to: Canagliflozin: First Global Approval. Drugs 73, 1847 (2013). https://doi.org/10.1007/s40265-013-0139-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-013-0139-7